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INTRODUCTION
Pediatric neurologists aim to provide swift and precise diag-
nosis as well as appropriate therapeutic and supportive man-
agement for children with neurological disorders and their 
families. Many different, often rare and severe, acquired as well 
as genetic disorders of the brain, spinal cord, and neuromuscu-
lar system are encountered in everyday practice.1 A diagnosis 
may lead to rational therapeutic choices and, even if no medical 
treatment is available, provide insights into the prognosis and 
recurrence risk of the disorder within the family.
Establishing a diagnosis is, in many cases, a complex, expen-
sive, and lengthy process involving burdensome procedures. 
This is especially the case for patients presenting with develop-
mental delay, movement disorders, neuromuscular disorders, 
severe epilepsy, and/or combinations thereof that are expected 
to be of genetic origin.2 The armamentarium to reach a diagno-
sis includes tests such as magnetic resonance imaging, electro-
encephalography, biochemical and metabolic blood tests, urine 
tests, and cerebrospinal fluid tests, muscle biopsy, genomic 
microarrays, and Sanger sequencing of one or more genes 
and multiple consultations from various medical specialists.2 
However, the diagnostic yield of each individual test is low.3,4 
Despite all efforts of doctors and patients, a definitive diagnosis 
is reached only for a minority of all children with a neurologi-
cal disorder of presumed genetic origin,3 leaving ample room to 
improve the diagnostic process.
Whole-exome sequencing (WES) has recently been proven 
to be of great potential value as a diagnostic tool in clinical 
practice. Successful application of WES in pediatric neurology 
has been confined mostly to single case reports and retrospec-
tive studies in which WES was used as a last-resource genetic 
test.5–11 However, prospective clinical utility studies of larger 
groups of patients have not yet been performed. Here, we pres-
ent such data for a cohort of 150 patients who received both 
the standard diagnostic assessment and WES, allowing a direct 
comparison of the performance of both trajectories.
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Purpose: Implementation of novel genetic diagnostic tests is gener-
ally driven by technological advances because they promise shorter 
turnaround times and/or higher diagnostic yields. Other aspects, 
including impact on clinical management or cost- effectiveness, are 
often not assessed in detail prior to implementation.
Methods: We studied the clinical utility of whole-exome sequenc-
ing (WES) in complex pediatric neurology in terms of diagnostic 
yield and costs. We analyzed 150 patients (and their parents) present-
ing with complex neurological disorders of suspected genetic origin. 
In a parallel study, all patients received both the standard diagnostic 
workup (e.g., cerebral imaging, muscle biopsies or lumbar punctures, 
and sequential gene-by-gene–based testing) and WES simultaneously.
Results: Our unique study design allowed direct comparison of 
diagnostic yield of both trajectories and provided insight into the 
economic implications of implementing WES in this diagnostic tra-
jectory. We showed that WES identified significantly more conclusive 
diagnoses (29.3%) than the standard care pathway (7.3%) without 
incurring higher costs. Exploratory analysis of WES as a first-tier 
diagnostic test indicates that WES may even be cost-saving, depend-
ing on the extent of other tests being omitted.
Conclusion: Our data support such a use of WES in pediatric neu-
rology for disorders of presumed genetic origin.
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MATERIALS AND METHODS
Patient recruitment, selection, and counseling
The Department of Pediatric Neurology at the Radboud 
University Medical Center is a tertiary referral center for pedi-
atric neurology. The majority of patients are referred by pedia-
tricians, neurologists, and psychiatrists for further diagnostics 
or second opinions.
A total of 150 consecutive patients with (nonacute) neuro-
logical symptoms of suspected genetic origin were selected. The 
group consisted of patients who were newly referred by either a 
general practitioner (n = 11) or a medical specialist (n = 55) and 
patients who had been referred to our center previously but still 
visited the outpatient clinic for diagnostic purposes because no 
conclusive diagnosis had been reached (n = 84). As such, the 
group was representative of pediatric patients presenting with 
complex neurological symptoms of suspected genetic origin 
seen in a tertiary referral center.
Family history was negative for 143 subjects. For the 7 others, 
diagnosis of a recessive disorder was expected based on affected 
siblings and/or parental consanguinity. Patients with well-
known, clinically easily recognizable genetic disorders such 
as neurofibromatosis type 1 were not included in this study. A 
clinical geneticist counseled all 150 patients and their parents 
regarding the WES procedure, and all participants or their legal 
representatives gave written informed consent. This study was 
approved by the Medical Review Ethics Committee Arnhem-
Nijmegen under the realm of clinical diagnostic genetic testing 
(2011/188).
Study design and classification of outcome of diagnostic 
workup
After inclusion, all patients received two diagnostic pathways 
in parallel, i.e., the standard diagnostic pathway and the WES 
pathway (Figure 1). Data regarding diagnostic tests and out-
comes were not exchanged between the two pathways prior to 
reaching a conclusion for each of them separately. All patients 
were followed for a minimum of 6 months after starting WES 
(median, 17 months; range, 6–42 months). The primary end 
point for this study was the diagnostic yield of both diagnostic 
pathways.
For the standard diagnostic pathway, the diagnostic workup 
was left to the discretion of the pediatric neurologists and was 
based on the clinical presentation of the patient. The outcome 
of this pathway was classified as follows:
1. There is no conclusive diagnosis. A clinical, descriptive, 
diagnosis can be reached, but genetic testing does not 
confirm this clinical descriptive diagnosis.
2. A conclusive diagnosis is reached. The clinical diagnosis 
is confirmed by the presence of a causative genetic vari-
ant (class 4 or 5)12 in a disease gene associated with the 
patient’s phenotype.
In the WES pathway, DNA of 150 patients and their parents 
(for 143 of 150 patients) was isolated from whole blood. Exome 
sequencing was performed according to our diagnostic proce-
dures under ISO15189 certification (Supplementary Table S1 and 
Supplementary Figure S1 online). Sequencing was performed to 
an approximate read depth of 70- to 100-fold. Variant calling and 
interpretation were performed essentially as described previously 
(Supplementary Table S1 online).13,14 First, an in silico gene-panel 
analysis was performed using the WES data by referring to the sit-
uation when variants, both single-nucleotide variants (SNV) and 
copy-number variations (CNV), in known genes for the patient’s 
phenotype are evaluated for pathogenicity (Supplementary Table 
S1 and Supplementary Figure S1 online). In a second step, vari-
ants outside the gene panel were evaluated for pathogenicity and 
relevance for disease (both SNV and CNV). Patients who were 
sequenced as singletons received SNV analysis of the respective 
disease gene panel(s) as well as CNV analysis limited to genes 
within the relevant disease gene panels (Supplementary Table S1 
and Supplementary Figure S1 online).
The results of the WES procedure were classified in accor-
dance with ACMG guidelines:12,13
1. There is no conclusive diagnosis: no obvious patho-
genic variant was detected that could potentially explain 
disease.
2. A possible diagnosis is obtained: variant(s) of unknown 
significance (class 3) in a gene(s) is identified in a dis-
ease gene that is associated with the patient’s phenotype 
or, alternatively, a pathogenic variant(s) (class 4 or 5) in 
a candidate disease gene(s) is identified with a potential 
relationship to the patient’s phenotype.
3. A conclusive diagnosis is obtained: a causative genetic 
variant (class 4 or 5) in a disease gene is associated with 
the patient’s phenotype.
Figure 1 Schematic representation of the parallel study design. 
Schematic outline of the parallel design of our study including 150 patients 
with complex pediatric neurological problems of presumed genetic origin. 
*To determine the cost-to-diagnosis ratio, health-care resource use prior to 
inclusion was collected from the first visit to hospital clinic.
150 consecutive patients consulted in
clinical practice of pediatric neurology
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Diagnostic end points for each of the care pathways were 
compared and discussed after completion of the diagnostic 
quest during monthly meetings and in the presence of molecu-
lar geneticists, clinical genetic laboratory specialists, clinical 
geneticists, and pediatric neurologists.
Diagnostic concordance between the standard care pathway 
and WES was measured by comparing diagnostic yield in the 
two pathways at individual patient levels.
Determining costs associated with the diagnostic 
pathways
To accurately estimate the costs associated with diagnostic tests 
in the standard diagnostic pathway, types and volumes of diag-
nostic tests used were determined for each patient individually. 
This included diagnostic tests that were performed after inclu-
sion of the patient (until a diagnosis was established) and diag-
nostic tests that had been used prior to inclusion in our hospital 
or elsewhere. For the latter, data were extracted from medical 
records and from referral letters.
For the costs of genetic testing in the WES pathway, we used 
€3,500 for a trio analysis and €1,800 for a singleton; these costs 
represented prices for diagnostic exome sequencing in our lab-
oratory (August 2016).15
To obtain an estimate of the costs associated with WES as 
a first-tier test for these patients, an exploratory analysis was 
conducted based on the following:
1. For children, when WES resulted in a conclusive diagno-
sis, conventional tests (and associated costs) performed in 
the standard pathway could have been precluded. To esti-
mate the magnitude of the substitutive effect of WES, the 
pediatric neurologists indicated for all 44 patients receiv-
ing a conclusive diagnosis what conventional diagnostic 
tests would—in the context of clinical practice—still have 
been performed. Additionally, we assumed that these 
patients would still have two physician visits (pre- and 
post-WES test counseling) and one telephone consulta-
tion to inquire about patients’ general well-being.
2. For children, when WES did not result in a conclusive 
diagnosis (n = 106), the costs of the conventional diag-
nostic tests would have remained identical with the 
exception of costs associated with genetic testing, which 
were replaced by those of diagnostic WES.
Unit cost prices were obtained from the Dutch Healthcare 
Authority (https://www.nza.nl/ organisatie/sitewide/english/). 
Such costs cover the test, the interpretation of its results, and 
the physician fee. All unit costs were converted to 2016 Euros. 
Because cost and utilization data are generally skewed, bootstrap 
simulations with 1,000 replications were performed to estimate 
the mean costs and utilization and 95% confidence intervals.16
RESULTS
Demographics
A total of 150 pediatric patients with complex neurological 
disorders of suspected genetic origin were included between 
November 2011 and January 2015. The median age of our 
study cohort at the time of inclusion was 5 years and 7 months 
(range, 5 months–18 year), and 53.3% of the patients were 
male (Supplementary Table S1 and Supplementary Figure 
S2 online). Patients were diagnosed according to the follow-
ing major clinical subgroups: intellectual disability (ID; 78 
patients), movement disorders (20 patients), neuromuscular 
disease (8 patients), epilepsy (5 patients), or a combination 
thereof, such as “ID+epilepsy” or “ID+movement disorder” (39 
patients; Supplementary Table S1 online). This cohort thereby 
represented the broad phenotypic spectrum of disorders seen 
in daily routine pediatric neurology care at tertiary referral cen-
ters in the Netherlands.
Diagnostic yield in the standard diagnostic pathway
In the standard diagnostic pathway, 11 (7.3%) of 150 patients 
obtained a conclusive diagnosis confirmed by genetic testing (Table 
1, Supplementary Table S2 online). These diagnoses included 
both well-known syndromes, such as Sotos syndrome (NSD1 point 
mutation) and fragile X syndrome ((CGG)n repeat expansion), 
and CNVs of various sizes ranging from a 2.2-Mb duplication to a 
mosaic whole chromosome 8 trisomy. On average, conclusive diag-
noses in the standard pathway were reached after 4.6 genetic tests 
(range, 2–7 tests; Supplementary Table S3 online).
Because it may be expected that patients receiving a con-
clusive diagnosis underwent either less (“easy to diagnose”) or 
more testing (“perseverance of continued diagnostic testing”), 
we compared whether patients receiving a conclusive diagno-
sis underwent fewer or more genetic tests than those without 
a diagnosis. However, there was no difference in the number 
of genetic tests in the standard pathway performed between 
patients who received a diagnosis and patients without one (P = 
0.58, two-tailed t-test).
Diagnostic yield using whole-exome sequencing
In the WES pathway, 44 patients (29.3%) received a conclusive 
diagnosis, including 26 clinically well-known syndromes (e.g., 
MECP2 syndrome, KBG syndrome; Table 1, Supplementary 
Table S2 online). For 13 patients, a de novo point mutation was 
identified in a recently reported disease gene (Table 1). In addi-
tion, five pathogenic CNVs were identified that ranged in size 
from 342 kb to a whole chromosome 8 trisomy. Of note, the 
44 patients who obtained a diagnosis using WES had under-
went an average of 4.7 genetic tests in the standard diagnostic 
pathway (range, 1–12), which was not different from those for 
patients who had tested negative according to WES (P = 0.23, 
two-tailed t-test).
In addition to 44 conclusive diagnoses, WES identified a pos-
sible diagnosis for 41 further patients (27.3%) by reporting on 
presumably disease-causing mutations in candidate disease 
genes (Supplementary Table S4 online).
Diagnostic concordance between the standard care 
pathway and WES
Next, we compared the diagnoses obtained at individual patient 
levels to determine the concordance between both pathways. In 
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total, 47 patients (31.3%) obtained a diagnosis through either 
the standard or the WES pathway (Table 2; Supplementary 
Table S2 online). For eight patients (17.0%), the same conclu-
sive diagnosis was obtained by both pathways. Three further 
patients (6.4%) received their genetic diagnosis only through 
the standard genetic care pathway, whereas 36 patients (76.6%) 
received their genetic diagnosis only through WES (Table 2; 
Supplementary Table S2 online). Statistical analysis comparing 
the overall diagnostic yields between both pathways indicated 
that the use of WES resulted in significantly more conclusive 
diagnoses than the standard care pathway (n = 11 vs. n = 44, 
P = 9.7 × 10–7, two-tailed Fisher’s exact test). The three genetic 
diagnoses that were not identified using WES included a 9-bp 
duplication event (patient 114), a repeat (CGG)n expansion in 
FMR1 (patient 43), and a mosaic 27 Mb duplication of chromo-
some 7 (patient 49) (Table 2; Supplementary Table S2 online).
Health-care resource use
To gain insight into the cost-to-diagnosis ratio, we collected the 
health-care resource use during the diagnostic process both ret-
rospectively (prior to inclusion to our study) and prospectively 
(after inclusion in our study). On average, patients had 23.3 
physician–patient contacts and an extensive diagnostic workup 
including various forms of imaging technology (n = 4.1 tests), 
neurophysiology examinations (n = 2.2 tests), genetic diagnos-
tic testing (n = 5.4 tests; Supplementary Table S3 online), (iv) 
metabolic assays (n = 0.5 assays), (v) basic clinical chemistry 
tests of blood, urine, and spinal fluid (n = 54.7 tests), and other 
diagnostic laboratory tests (n = 2.2; Table 3).
Total costs for the standard diagnostic pathway, on aver-
age, amounted to €10,685 per patient (95% confidence inter-
val: €9,544–€11,909), of which genetic testing was the major 
driver of diagnostic costs (€4,164); 150 patients received 806 
genetic tests, with an average of 5.4 genetic tests per patient 
(range, 0–28 tests; Table 3; Supplementary Figures S3 and S4 
and Supplementary Table S3 online). Of note, patients who 
were already in a diagnostic trajectory in our university hospi-
tal before inclusion, on average, underwent significantly more 
genetic tests (n = 6.6) than patients that were either referred by 
a general practitioner (n = 2.9; P < 0.01) or referred by a periph-
eral hospital (n = 4.1; P < 0.01).
In comparison, the average cost of WES-based genetic test-
ing in this cohort was €3,420. Consequently, substitution of 
conventional genetic testing by WES in this cohort resulted in 
an average cost saving of €744 per patient. Notably, 17 patients 
(11.3%) received additional diagnostic testing as a consequence 
of the WES diagnostic report to support or decline the WES 
diagnosis (Supplementary Figure S5 and Supplementary 
Table S5 online).
Our exploratory analysis of the costs of diagnosis if WES 
were used as a first-tier test indicated that for 36 of 44 patients 
in whom WES led to a conclusive diagnosis, no additional tests 
would have been performed. The remaining eight patients 
would still have undergone additional (confirmatory) diag-
nostic tests ranging from a single cerebral imaging test or 
metabolic investigation to all diagnostic workup as performed 
before (Supplementary Figure S6 and Supplementary Table 
S6 online). Taking this into account, the mean costs of diagnos-
tic tests in our patient cohort would have amounted to €8,356 
(95% CI: €7,591–9,247) per patient. For patients with a con-
clusive WES diagnosis, those costs could be further reduced to 
€4,349 (95% CI: €3,994–4,777) because only limited other diag-
nostic testing would be required; however, for patients with a 
negative WES diagnosis, those costs would be €10,035 (95% CI: 
€9,312–10,797) because the remainder of the diagnostic path-
way would remain the same (Supplementary Figure S6 online; 
Supplementary Table S6 online).
DISCUSSION
Over the past few years, WES has been implemented in rou-
tine diagnostic genetic testing for clinically and genetically 
heterogeneous disorders.13,17–20 This implementation was 
technology-driven and based largely on the added diagnostic 
value obtained for patients who had reached the end stage in 
the standard diagnostic pathway. Here, we performed a clinical 
utility study using a design in which 150 consecutive patients 
with complex pediatric neurological disorders received both 
the standard diagnostic pathway as well as WES in parallel to 
determine the value of WES in pediatric neurology care. Using 
this study design, we were able to show that WES provides sig-
nificantly more conclusive genetic diagnoses than the standard 
genetic care, without incurring higher costs.
WES was able to provide a conclusive diagnosis for 44 
(29.3%) of 150 patients, whereas the standard diagnostic path-
way was only able to provide a diagnosis for 11 patients (7.3%). 
The overall diagnostic yield for the different clinical entities as 
seen in pediatric neurology is in agreement with previous stud-
ies reporting on the diagnostic yield of WES for each of these 
entities (Supplementary Table S7 online). Despite the relatively 
high number of conclusive diagnoses by WES, three disease-
causing mutations were identified only by standard genetic 
analysis. The three disease-causing mutations not identified by 
WES were directly related to technical pitfalls of WES. Two of 
three were not detected using the SNV detection tool, including 
a (CGG)n repeat expansion, which cannot be mapped because 
of the high repeat content of the expansion and a 9-bp duplica-
tion that was not mapped owing to relatively long duplication 
in an homopolymer (G) stretch in relation to the length of the 
Table 2 Diagnostic concordance between standard genetic 
care pathway and WES
WES pathway
TotalConclusive Possible No
Standard care 
pathway
Conclusive 8 – 3 11
No 36 41 62 139
Total 44 41 65 150
WES, whole-exome sequencing.
Details of the conclusive diagnosis obtained are listed in Table 1, whereas 
Supplementary Tables S2 and S4 online show concordance between diagnostic 
pathways and an overview of the 41 possible diagnoses, respectively.
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sequence read. The third, a mosaic 27 Mb duplication, was not 
detected by the CNV detection tool. In retrospect, the latter 
mosaic duplication could be detected upon visual inspection of 
the data. Optimization of both the sequencing technology and 
the bioinformatic algorithms dedicated to the detection of such 
variants (both at SNV and CNV level) would eventually over-
come these current technological pitfalls. In this respect, much 
progress is to be expected from genome (long-read) sequencing 
Table 3 Health-care resource use in the standard diagnostic trajectory
Bootstrapped mean quantity per patient 
(95% confidence interval)
Bootstrapped mean costs (€) per patient 
(95% confidence interval)
Physician–patient contact
Consultations 11.80 (9.43–14.55) 1,921.54 (1,535.41–2,372.19)
Telephone 11.31 (9.15–13.55) 192.26 (155.62–230.33)
Subtotal contacts 23.27 (19.13–28.18) 2,120.96 (1,728.64–2,593.98)
Imaging technology
Magnetic resonance imaging 1.72 (1.48–2.03) 425.53 (362.85–505.39)
Radiography (x-ray) 0.78 (0.53–1.03) 54.09 (37.08–71.77)
Ultrasonography (echo) 1.17 (0.83–1.57) 106.28 (74.89–143.5)
Computed tomography 0.19 (0.09–0.31) 27.34 (13.16–44.34)
Other 0.24 (0.09–0.44) 98.09 (39.62–166.71)
Subtotal imaging 4.10 (3.36–4.87) 709.04 (593.04–833.19)
Neurophysiology examinations
Electroencephalogram 1.52 (1.14–1.93) 497.29 (374.07–635.66)
Electrophysiology 0.15 (0.08–0.24) 27.84 (11.96–48.12)
Other 0.53 (0.35–0.73) 77.57 (51.99–107.87)
Subtotal neurophysiology 2.19 (1.72–2.74) 602.50 (466.02–754.10)
Genetic
Genomic microarray 1.05 (0.93–1.19) 813.81 (720.90–917.98)
Karyotyping 0.28 (0.2–0.37) 215.46 (154.55–283.35)
Fluorescent in situ hybridization 0.07 (0.03–0.12) 56.28 (25.76–92.73)
Multiplex dependent probe amplification 0.25 (0.17–0.34) 196.46 (134.61–264.23)
Chromosome X-inactivation studies 0.01 (0–0.03) 10.30 (0–25.76)
Cytogenetic screening (n.o.s.) 0.04 (0–0.10) 31.78 (0–74.78)
Mitochondrial DNA diagnostics 0.40 (0.26–0.56) 312.55 (200.79–432.75)
Sanger sequencing 3.27 (2.67–3.91) 2,524.60 (2,065.59–3,024.20)
Subtotal genetics 5.39 (4.73–6.12) 4,164.29 (3,654.41–4,726.30)
Metabolic testing
Mitochondrial enzymes diagnostics 0.19 (0.11–0.29) 190.57 (108.42–287.41)
Lysosomal enzymes 0.27 (0.18–0.35) 263.41 (178.67–351.28)
Mitochondrial biochemical diagnostics 0.05 (0.01–0.10) 48.44 (7.09–106.33)
Complex 1 deficiency testing 0.01 (0–0.02) 6.25 (0–19.8)
Mitochondrial analysis (n.o.s.) 0.03 (0–0.05) 20.96 (0–34.9)
Subtotal metabolics 0.54 (0.41–0.70) 530.93 (398.19–688.95)
Routine biochemical assays
Blood 36.77 (30.09–44.7) 1,449.99 (1,235–1,687.74)
Urine 11.75 (8.58–15.55) 138.37 (106.28–181.54)
Cerebrospinal fluid 6.12 (4.56–7.89) 205.18 (144.82–270.67)
Subtotal routine labs 54.67 (44.94–65.76) 1,799.88 (1,567.09–2,045.72)
Other diagnostics
Biopsy (lumbar puncture) 0.35 (0.26–0.44) 58.57 (44.16–73.41)
Biopsy, histology 0.34 (0.25–0.44) 19.59 (14.16–25.26)
Biopsy, metabolic 0.41 (0.29–0.54) 405.26 (287.41–530.11)
Other 1.07 (0.74–1.43) 304.34 (220.42–395.05)
Subtotal others 2.17 (1.67–2.73) 786.88 (594.1–987.89)
Total tests/costs 91.90 (77.8–108.14) 10,684.85 (9,543.87–11,908.55)
n.o.s., not otherwise specified
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technologies because these will also capture (non-)coding vari-
ants and structural variation that currently remain undetected 
by WES.7,21,22
The standard care pathway did not identify 36 conclusive 
genetic diagnoses, including those of 21 known syndromes. 
This lack of conclusive diagnoses for known syndromes may 
be explained by three main factors. First, the median age of 
our patient cohort was low and young patients may not (yet) 
display all characteristic clinical features of the syndrome. 
Second, previous genetic testing may not have uncovered the 
causal variant. For two patients, we identified a CNV explain-
ing the patients’ phenotype despite the fact that those patients 
underwent genomic microarray-based testing in their stan-
dard genetic pathway. Retrospective analysis of these original 
array data indicated that these two regions were poorly covered 
on the array, thereby explaining why these escaped detection 
(Supplementary Figure S7 online). Third, the clinical and 
genetic heterogeneity of the disorders encountered in pediatric 
neurology clinic is enormous. 
Over the past few years, the use of next-generation sequenc-
ing technologies has led to the discovery of many novel dis-
ease-causing genes, especially for clinically and genetically 
heterogeneous disorders.23 This makes it virtually impossible 
to keep up to date on all genes involved in the respective dis-
eases, thereby limiting the possibility to request the right gene 
for targeted mutation analysis. Patient 37, who received a clini-
cal diagnosis of Kabuki syndrome, exemplified this situation. 
KMT2D, which causes Kabuki syndrome when mutated, was 
tested but no mutations were identified. Then, WES identified 
a disruptive mutation in KDM6A. Mutations in the KDM6A 
gene also cause Kabuki syndrome, but this was published24 only 
weeks after the patient was last seen by the medical specialist. 
This difficulty is further underscored by the fact that 13 of 44 
(30%) of the conclusive WES diagnoses involved a gene that has 
been implicated in disease only in the past few years.
WES provided a possible genetic diagnosis for another 41 
patients (27%). Although further clinical and genetic follow-up 
for larger cohorts of patients with similar phenotypic character-
istics is required to establish the true nature of these diagnoses, 
our experience has shown that up to two-thirds of these possi-
ble diagnoses will be revised to conclusive diagnoses once addi-
tional patients with mutations in the same gene are identified 
and characterized.13,25,26 Moreover, with increasing knowledge 
over time and more genes being implicated in disease, WES 
data can be revisited and reinterpreted, and more conclusive 
diagnoses can be made. For instance, 3 of 106 WES-negative 
patients have already obtained a conclusive genetic diagnosis 
since our data freeze (July 2015), based on the availability of 
new clinical information and targeted reanalysis of existing 
WES data. Although speculative, it can be anticipated that the 
conclusive diagnostic yield of WES in this cohort may be as 
high as 50%, but this would require regular reanalysis of the 
available WES data.
In this study, we gathered data regarding health-care resource 
use to gain insight into the cost-to-diagnosis ratio in both the 
standard pathway and the WES genetic diagnostic tract. The 
standard care pathway results in a mean cost of €10,685 per 
patient, with €4,164 for genetic testing. Replacing all diagnos-
tic efforts in this cohort by WES increased the diagnostic yield 
while reducing the expenses for genetic testing by €744. Our 
study thus determined the potential savings resulting from clin-
ical implementation of WES, albeit for the Dutch health-care 
system. In this system, all patients (and parents) received com-
plete insurance coverage for their diagnostic pathway, including 
the genetic tests. Patients who were already in a diagnostic tra-
jectory in our hospital prior to study inclusion had undergone 
more genetic tests than patients who were newly referred. This 
suggests that the cost-to-diagnosis ratio could be reduced if cli-
nicians perform WES instead of the conventional genetic tests 
during an earlier stage of the diagnostic trajectory. Moreover, 
it may be suggested that extensive (genetic) diagnostic workup 
after a negative WES result be refrained from in order to reduce 
the cost-to-diagnosis ratio even more. This is because our data 
show that only 2% of patients with a negative WES report 
obtained a conclusive diagnosis using the standard diagnostic 
workup and costs associated with these additional diagnoses 
are immense. Considering cost-effectiveness, it is also notewor-
thy that a reduction in the cost-to-diagnosis ratio in a WES-first 
approach may only be obtained for certain pediatric patients 
with complex phenotypes because patients with less complex 
phenotypes may be easier to diagnose with cheaper targeted 
testing such as gene-panel strategies. Additionally, given the 
worldwide differences in prices for diagnostic WES11 and other 
(genetic) diagnostic tests analyzed in our study, the extensibility 
and translation of our cost analyses to other health-care sys-
tems and countries require further studies.
A more precise (genetic) diagnosis may have a major impact 
on clinical management and facilitates personalized medicine. 
For instance, in patient 146, who had been diagnosed with an 
SCN8A mutation, the antiepileptic drug was changed to oxcar-
bazepine, which exerts its action by blocking voltage-sensitive 
sodium channels. In our study, we revisited the diagnostic care 
pathways of our patients and evaluated what changes could 
have been made if WES had been the first-tier diagnostic test. 
Importantly, for 36 of 150 patients (24%) the diagnostic pro-
cess would have been limited to WES and patients would not 
have undergone additional (invasive) medical procedures. We 
have previously reported the time to diagnosis for 50 of the 
150 patients in the conventional pathway,3 which showed that 
the mean duration is at least 40 months. Routine turnaround 
times of WES are 4–6 months worldwide, which can probably 
be reduced to weeks27,28 by further automation and streamlining 
of the laboratory and interpretation process.
One aspect of responsible health-care innovation and 
changes in diagnostic pathways is the perception, expectations, 
and needs of the end users of the novel product. We have pre-
viously explored the parents’ information and communication 
needs in the counseling strategies for diagnostic WES using 
in-depth semi-structured interviews with 15 families of our 
cohort.29 Additionally, we investigated the psychosocial effects 
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of WES diagnoses.30 Whereas our interviews did not identify 
any major hurdles for widespread implementation of WES as a 
(first-tier) diagnostic test, which is in line with other studies,31 
the interviews did emphasize that a diagnosis has a broader 
impact than just a medical one.29,30 The latter was highlighted by 
novel (psychosocial) uncertainties that parents face when their 
child is diagnosed with a rare genetic disease for which little 
is known and only a few patients have been diagnosed with 
worldwide. Also, parents reported the need for more postcoun-
seling advice, which can be fulfilled by a genetic counselor who, 
after the diagnosis, maintains long-term contact with the fam-
ily and helps with everyday problems associated with having a 
child with a (rare) genetic disease. Another important aspect 
of patient empowerment is the disclosure of incidental find-
ings and related consent procedures.32–35 Several groups have 
reported incidental findings that vary between 1.2 and 4.6% for 
patients undergoing WES.36,37 However, our study did not reveal 
any. Nonetheless, the detailed interviews with parents did indi-
cate that a tailor-made disclosure policy for incidental findings 
is warranted, which is in accordance with previous studies.38,39
In conclusion, we performed a study of the diagnostic yield 
and costs of WES in pediatric neurology as compared to the 
conventional diagnostic trajectory. Our data show that WES 
provides more conclusive genetic diagnoses than standard 
(genetic) care without incurring higher costs. Moreover, in 
this patient population, a reduction of costs associated with 
obtaining a molecular diagnosis may be achieved if WES were 
used as the first-tier test, thereby partially substituting imaging 
studies, biopsies, and lumbar punctures and replacing conven-
tional genetic diagnostics. Our data support a change in clini-
cal pediatric neurology practice toward WES as a first-tier test 
in the diagnostic trajectory of patients presenting with com-
plex neurological disorders of presumed genetic origin.
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